Agomelatine

Agomelatine

Clinical data
Trade names	Melitor, Thymanax, Valdoxan
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Valdoxan
Pregnancy category	AU: B1
Routes of administration	Oral
ATC code	N06AX22 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	1%
Protein binding	95%
Metabolism	hepatic (90% CYP1A2 and 10% CYP2C9)
Biological half-life	1-2 hours
Excretion	Renal (80%, mostly as metabolites)
Identifiers
IUPAC name N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
CAS Number	138112-76-2 N
PubChem (CID)	82148
IUPHAR/BPS	198
DrugBank	DB06594 N
ChemSpider	74141 Y
UNII	137R1N49AD Y
KEGG	D02578 Y
ChEMBL	CHEMBL10878 Y
ECHA InfoCard	100.157.896
Chemical and physical data
Formula	C15H17NO2
Molar mass	243.301 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(NCCc1c2c(ccc1)ccc(OC)c2)C
InChI InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) Y Key:YJYPHIXNFHFHND-UHFFFAOYSA-N Y
NY (what is this?)

Agomelatine (BAN, rINN; trade names Valdoxan, Melitor, Thymanax) is a melatonergic antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder, primarily for its relatively favorable side effect profile: it avoids the weight gain, sexual dysfunction, and severe withdrawal associated with the most commonly used classes of antidepressants (SSRIs, SNRIs, tricyclics), while providing similar therapeutic benefit.

Due to its distinctive mechanism of action, agomelatine is also studied for its effects on sleep regulation. Studies report various improvements in general quality of sleep metrics, as well as specific therapeutic benefits in circadian rhythm disorders.

Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continued to develop the drug and conduct phase III trials in the European Union.

In March 2005, Servier submitted agomelatine to the European Medicines Agency (EMA) under the trade names Valdoxan and Thymanax. On 27 July 2006, the Committee for Medical Products for Human Use (CHMP) of the EMA recommended a refusal of the marketing authorisation. The major concern was that efficacy had not been sufficiently shown, while there were no special concerns about side effects. In September 2007, Servier submitted a new marketing application to the EMA.